• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Zynerba Pharmaceuticals Inc.

    9/5/23 4:39:51 PM ET
    $ZYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZYNE alert in real time by email
    SC 13G 1 zyne13g.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. ___)*

     

     

    Zynerba Pharmaceuticals, Inc.

    (Name of Issuer)

     

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

     

    98986X109

    (CUSIP Number)

     

     

    August 24, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [X]       Rule 13d-1(b)

     

    [X]       Rule 13d-1(c)

     

    [ ]       Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     1 
    CUSIP No. 98986X109

     

     

    1.Names of Reporting Persons.


    Beryl Capital Management LLC

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)     X     

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 4,426,381

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 4,426,381

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 4,426,381

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 8.2%

     

    12. Type of Reporting Person (See Instructions) IA, OO

     2 
    CUSIP No. 98986X109

     

     

    1.Names of Reporting Persons.


    Beryl Capital Management LP

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)     X     

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 4,426,381

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 4,426,381

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 4,426,381

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 8.2%

     

    12. Type of Reporting Person (See Instructions) IA, PN

     3 
    CUSIP No. 98986X109

     

     

    1.Names of Reporting Persons.


    Beryl Capital Partners II LP

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)          

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 3,904,692

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 3,904,692

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 3,904,692

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 7.2%

     

    12. Type of Reporting Person (See Instructions) PN

     4 
    CUSIP No. 98986X109

     

    1.Names of Reporting Persons.


    David A. Witkin

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)     X     

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization U.S.A.

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 4,426,381

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 4,426,381

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 4,426,381

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 8.2%

     

    12. Type of Reporting Person (See Instructions) IN, HC

     5 
    CUSIP No. 98986X109

    Item 1.

     

    (a)Name of Issuer

    Zynerba Pharmaceuticals, Inc.

     

    (b)Address of Issuer's Principal Executive Offices

    80 W. Lancaster Avenue, Suite 300, Devon, PA 19333

     

    Item 2.

     

    (a)The names of the persons filing this statement are:

    Beryl Capital Management LLC (“Beryl”), Beryl Capital Management LP (“Beryl GP”), Beryl Capital Partners II LP (the “Partnership”) and David A. Witkin (collectively, the “Filers”). Each Filer disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    (b)The principal business office of the Filers is located at:

    225 Avenue I, Suite 205, Redondo Beach, CA 90277

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s Common Stock, par value $0.001 per share (the "Stock").

     

    (e)The CUSIP number of the Issuer is: 98986X109

     

     

     6 
    CUSIP No. 98986X109

     

    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)[X] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E), as to Beryl and Beryl GP.

     

    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

     

    (g)[X] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G), as to Mr. Witkin.

     

    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j)[ ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J).

     

    (k)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution _______________________________________________________________.

     

    Item 4.Ownership.

     

    See Items 5-9 and 11 of the cover page for each Filer.

     

    The percentages reported in this Schedule 13G are based on 53,939,431 shares of Common Stock outstanding as of August 9, 2023, as reported in the Form 10-Q filed by the Issuer on August 14, 2023.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Beryl is the investment adviser to the Funds and other accounts. Beryl is the general partner of Beryl GP, which is the general partner of one or more of the Funds. Mr. Witkin is the control person of Beryl.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Material to Be Filed as Exhibits

    Exhibit A Joint Filing Agreement.

    Item 11.Certification of Beryl, Beryl GP and Mr. Witkin.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Certification of the Partnership.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     7 
    CUSIP No. 98986X109

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: September 5, 2023

     

    BERYL CAPITAL MANAGEMENT LLC  

    BERYL CAPITAL MANAGEMENT LP

     

          By: Beryl Capital Management LLC
            General Partner
    By: /s/ Andrew Nelson      
      Andrew Nelson     By: /s/ Andrew Nelson  
      Chief Operating Officer and CFO       Andrew Nelson  
            Chief Operating Officer and CFO  
    BERYL CAPITAL PARTNERS II LP    
         
    By: Beryl Capital Management LP   /s/ David A. Witkin
    General Partner   David A. Witkin
         
    By: Beryl Capital Management LLC    
    General Partner    
         
    By:/s/ Andrew Nelson    
    Andrew Nelson    
    Chief Operating Officer    
     8 
    CUSIP No. 98986X109

     

    EXHIBIT A

     

    AGREEMENT REGARDING JOINT FILING

    OF STATEMENT ON SCHEDULE 13D OR 13G

     

    The undersigned agree to file jointly with the Securities and Exchange Commission (the "SEC") any and all statements on Schedule 13D or Schedule 13G and Forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Beryl Capital Management, LLC, a Delaware limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

     

     

    Dated: September 5, 2023

     

    BERYL CAPITAL MANAGEMENT LLC  

    BERYL CAPITAL MANAGEMENT LP

     

          By: Beryl Capital Management LLC
            General Partner
    By: /s/ Andrew Nelson      
      Andrew Nelson     By: /s/ Andrew Nelson  
      Chief Operating Officer and CFO       Andrew Nelson  
            Chief Operating Officer and CFO  
    BERYL CAPITAL PARTNERS II LP    
         
    By: Beryl Capital Management LP   /s/ David A. Witkin
    General Partner   David A. Witkin
         
    By: Beryl Capital Management LLC    
    General Partner    
         
    By:/s/ Andrew Nelson    
    Andrew Nelson    
    Chief Operating Officer    

     

     

    Get the next $ZYNE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZYNE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ZYNE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE

      New product in development diversifies portfolio to drive long-term growth  Innovative potential new therapeutic option for rare/orphan neuropsychiatric disorders with high unmet medical needs Zygel™ in pivotal Phase 3 trial for Fragile X syndrome and has completed Phase 2 proof-of-concept study in 22q11.2 deletion syndrome PLYMOUTH MEETING, Pa., Oct. 11, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it has completed its acquisition of Zynerba Pharmaceuticals, Inc. ("Zynerba") (NASDAQ:ZYNE).

      10/11/23 8:00:00 AM ET
      $HRMY
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions

      DEVON, Pa., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today reminds all stockholders, including individual stockholders, to promptly tender their shares into the tender offer (the "Offer") by Harmony Biosciences Holdings, Inc. ("Harmony") and its wholly owned subsidiary, Xylophone Acquisition Corp. ("Purchaser"), to purchase all outstanding shares of Zynerba common stock. The Zynerba Board of Directors unanimously recommends that Zynerba stockholders tender their shares pursuant to the Offer. Key Information to Know Tender Deadl

      10/4/23 4:05:00 PM ET
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023

      DEVON, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today released the following letter to stockholders concerning the pending tender offer by Harmony Biosciences Holdings, Inc. ("Harmony"). Fellow Zynerba Pharmaceuticals Stockholders, We urge you to promptly tender your shares in response to the pending tender offer (the "Offer") by Harmony and its wholly owned subsidiary, Xylophone Acquisition Corp. ("Purchaser"). As previously disclosed, the Offer is to purchase all of the issued and outstanding shares of the co

      9/29/23 9:00:00 AM ET
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYNE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital reiterated coverage on Zynerba Pharmaceuticals with a new price target

      Roth Capital reiterated coverage of Zynerba Pharmaceuticals with a rating of Buy and set a new price target of $7.25 from $8.00 previously

      3/10/21 4:21:24 PM ET
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity resumed coverage on Zynerba Pharmaceuticals with a new price target

      Canaccord Genuity resumed coverage of Zynerba Pharmaceuticals with a rating of Buy and set a new price target of $18.00

      2/5/21 4:18:35 AM ET
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYNE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Jones Kenneth T was granted 30,000 shares, closing all direct ownership in the company (SEC Form 4)

      4 - Zynerba Pharmaceuticals, Inc. (0001621443) (Issuer)

      10/11/23 10:17:14 AM ET
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stephenson Pamela closing all direct ownership in the company (SEC Form 4)

      4 - Zynerba Pharmaceuticals, Inc. (0001621443) (Issuer)

      10/11/23 10:12:57 AM ET
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fickenscher James E was granted 170,000 shares, closing all direct ownership in the company (SEC Form 4)

      4 - Zynerba Pharmaceuticals, Inc. (0001621443) (Issuer)

      10/11/23 10:12:34 AM ET
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYNE
    SEC Filings

    See more
    • SEC Form 15-12G filed by Zynerba Pharmaceuticals Inc.

      15-12G - Zynerba Pharmaceuticals, Inc. (0001621443) (Filer)

      10/19/23 4:48:36 PM ET
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Zynerba Pharmaceuticals Inc.

      EFFECT - Zynerba Pharmaceuticals, Inc. (0001621443) (Filer)

      10/12/23 12:15:05 AM ET
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form POS AM filed by Zynerba Pharmaceuticals Inc.

      POS AM - Zynerba Pharmaceuticals, Inc. (0001621443) (Filer)

      10/11/23 9:27:41 AM ET
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYNE
    Financials

    Live finance-specific insights

    See more
    • HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE

      New product in development diversifies portfolio to drive long-term growth  Innovative potential new therapeutic option for rare/orphan neuropsychiatric disorders with high unmet medical needs Zygel™ in pivotal Phase 3 trial for Fragile X syndrome and has completed Phase 2 proof-of-concept study in 22q11.2 deletion syndrome PLYMOUTH MEETING, Pa., Oct. 11, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it has completed its acquisition of Zynerba Pharmaceuticals, Inc. ("Zynerba") (NASDAQ:ZYNE).

      10/11/23 8:00:00 AM ET
      $HRMY
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.

      PLYMOUTH MEETING, Pa. and DEVON, Pa., Aug. 14, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced a definitive agreement to acquire Zynerba Pharmaceuticals, Inc. ("Zynerba") (NASDAQ:ZYNE), a leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, including Fragile X syndrome (FXS). Under the terms of the definitive agreement, Harmony

      8/14/23 7:30:00 AM ET
      $HRMY
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome

      – The INSPIRE trial achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments – – Safety data reinforce excellent tolerability profile of Zygel – – Company will focus resources on FXS and 22q development – – Cash runway extended through the end of 2023 / early 2024 – – Zynerba to host conference call and webcast tomorrow, June 22, 2022 at 9:00 a.m. ET – DEVON, Pa., June 21, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced positive top line results from the explorat

      6/21/22 8:05:00 PM ET
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYNE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Zynerba Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Zynerba Pharmaceuticals, Inc. (0001621443) (Subject)

      2/8/24 7:22:51 PM ET
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Zynerba Pharmaceuticals Inc.

      SC 13G - Zynerba Pharmaceuticals, Inc. (0001621443) (Subject)

      9/5/23 4:39:51 PM ET
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Zynerba Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Zynerba Pharmaceuticals, Inc. (0001621443) (Subject)

      2/14/22 3:52:48 PM ET
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYNE
    Leadership Updates

    Live Leadership Updates

    See more
    • Zynerba Pharmaceuticals Announces Planned Retirement of Suzanne Hanlon and Appoints Albert P. Parker as Chief Legal Officer

      DEVON, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the appointment of Albert P. Parker, an accomplished industry executive with over 25 years of pharmaceutical, biotech and healthcare experience, as Chief Legal Officer and Corporate Secretary. He will assume the duties of Suzanne Hanlon who will retire from her position at the end of February 2022. "We are excited to have Al join our senior leadership team. He is an experienced legal and business executive who brings significant strategic and hands-o

      2/15/22 7:00:00 AM ET
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunome Provides Organizational Update: Appoints Richard Baron to its Board of Directors and Sandra Stoneman as Chief Legal Officer and Corporate Secretary

      EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, with a focus on oncology and infectious diseases including COVID-19, today announced the recent appointments of Richard Baron to Immunome’s Board of Directors and as Audit Committee Chair, and Sandra Stoneman, Esq. as Chief Legal Officer and Corporate Secretary. The company also today announced that its President and Chief Executive Officer, Purnanand Sarma, Ph.D. is the recipient of TiE Boston’s 2020 Lifetime Achievement Award. The award recognizes individuals who have made invaluab

      12/10/20 8:00:00 AM ET
      $GMED
      $PUMP
      $ZYNE
      Medical/Dental Instruments
      Health Care
      Oilfield Services/Equipment
      Energy